- Amgen's dazodalibep met the primary endpoint in the Phase 3 OASIZ 301 trial for moderate-to-severe Sjögren's disease.
Amgen's Phase 3 OASIZ 301 trial for dazodalibep in moderate-to-severe Sjögren's disease met its primary endpoint. The 621-patient study showed significant improvement in systemic disease activity by Week 4, sustained through Week 48. No FDA-approved therapies exist. A second Phase 3 study (OASIZ 303) in symptomatic Sjögren's is expected to complete in Q4.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.